Paradigm Biopharmaceuticals Ltd has released a press release.
Response to ASX Price Query
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- 2024 Chairman Address and AGM Presentation
- Phase 3 Protocol Submission to US FDA
- Paradigm Investor Update
- PAR receives positive response from US FDA for phase 3
- Appendix 4E and 2024 Annual Report
Later from Paradigm Biopharmaceuticals
- Paradigm to Proceed with Phase 3 Knee OA Trial
- Trading Halt
- Successful Completion of $16M Placement for Phase 3
- PAR Capital Raising Presentation
- Paradigm Receives $6.3m R&D Tax Refund
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals